Motilal Oswal's research report on Ajanta Pharma
Ajanta Pharma (AJP) delivered better-than-expected 3QFY24 performance, led by strong growth in the Asia and Africa region. Domestic formulation (DF) exhibited muted growth, due to addition of a brand under National list of Essential medicine (NLEM). AJP would end FY24 on a strong recovery in profitability compared to that in FY23.
Outlook
We raise our earnings estimate by 9%/6%/3% for FY24/FY25/FY26, factoring a) better-than-industry growth in the branded generics market, b) improved traction in institutional anti-malaria business and c) controlled opex. We value AJP at 26x 12M forward earnings to arrive at a price target of INR2,515.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
